ABRF 2022: Targeted UPLC-MS/MS Lipidomics for Biomarker Research of Prostate Cancer (PCa) and Therapy Responses in Human Serum

Significance of the topic

Prostate cancer accounts for nearly 40% of male cancer diagnoses worldwide, yet current blood-based screening methods such as prostate-specific antigen (PSA) measurements suffer from limited specificity and sensitivity.
Emerging research indicates that alterations in lipid metabolism may yield robust biomarkers for disease detection and therapeutic monitoring.

Aims and overview of the study

The primary goals of this work were to:

• Implement a targeted UPLC-MS/MS lipidomics workflow (LipidQuan™) to detect and quantify candidate lipid biomarkers in human serum.
• Evaluate the method’s ability to distinguish between prostate cancer patients and controls, as well as to monitor lipid profile changes in therapy-treated individuals.

Methods and instrumentation

Serum samples were collected from prostate cancer patients (diagnosed and hormone therapy-treated) and matched controls. Lipids were extracted using standard protocols prior to analysis by ultra performance liquid chromatography (UPLC) with hydrophilic interaction liquid chromatography (HILIC) separation, coupled to tandem quadrupole mass spectrometry operated in multiple reaction monitoring (MRM) mode.
Instrumentation details:

• Waters UPLC system with HILIC column for class-based lipid separation.
• Tandem quadrupole MS detector operated in MRM for targeted quantification.
• Use of class-specific internal standards and calibrants to achieve accurate quantitation.

Main results and discussion

The targeted assay monitored 39 key lipid species across major classes such as lysophosphatidylethanolamines (LPEs), sphingomyelins (SMs), and ceramides (Cers). Key findings included:

• Establishment of linear dynamic ranges exceeding three orders of magnitude, enabling accurate detection at low endogenous serum concentrations.
• HILIC-based separation effectively resolved lipid classes, minimizing isomeric and isobaric interferences.
• Hormone therapy-treated patients exhibited significant upregulation of several LPE species compared to untreated prostate cancer controls, suggesting potential markers of treatment response.

Benefits and practical applications

• High throughput and sensitivity suitable for clinical biomarker screening.
• Reduced need for multiple calibrants and standards, lowering operational costs.
• Robust class-based separation simplifies data analysis and enhances quantitation reliability.
• Integrates seamlessly with proteomics workflows for comprehensive multi-omics studies.

Future trends and applications

Continued development of targeted lipidomics is expected to expand biomarker panels for personalized prostate cancer diagnosis and monitoring. Integration with high-resolution MS platforms and advanced data analytics may enable real-time therapeutic decision support and multi-omics profiling for precision medicine.

Conclusion

The LipidQuan™ UPLC-MS/MS method demonstrates rapid, sensitive, and quantitative analysis of lipid biomarkers in human serum, offering a promising tool for advancing prostate cancer diagnostics and therapy response monitoring in clinical research settings.

References

1. Worldwide cancer statistics. Cancer Research UK.
2. Drabovich, A.P. et al. Mol. Cell. Proteomics 18, 1807–1823 (2019).
3. Lloyd-Price, J. et al. Nature 569, 655–662 (2019).
4. Zhou, X. et al. PLoS One 7(11) (2012).
5. Perrotti, F. et al. Int. J. Mol. Sci. 17(12) (2016).
6. Isaac, G. et al. Waters Application Note 720006402EN (2018).